Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6ENSJ)

• Drug Name: Tralokinumab Drug Info
• Synonyms: CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Approved	[1]
Ulcerative colitis	DD71	Phase 3	[2]
Asthma	CA23	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DM6ENSJ

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[6]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[7]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[8]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[9]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[6]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[10]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[11]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[12]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[11]
CNTO-5825	DMF8WAT	Allergic asthma	CA23.0	Phase 1	[13]

Drug(s) Targeting Interleukin 13 receptor alpha-2 (IL13RA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICT-107	DMBIZ7H	Brain cancer	2A00	Phase 3	[14]
ABT-308	DM6WN2D	Eosinophilic esophagitis	DA24.1	Phase 2	[15]
MB-101	DMLA1QD	Recurrent glioblastoma	2A00.00	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Inhibitor	[4]
Interleukin 13 receptor alpha-2 (IL13RA2)	TTMPZ7V	I13R2_HUMAN	Modulator	[5]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
• [3] ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
• [6] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [7] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [8] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [9] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [10] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [11] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [12] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
• [13] Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
• [14] Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)